Published in Rev Urol on January 01, 2006
Strategy for reversing resistance to a single anticancer agent in human prostate and pancreatic carcinomas. Proc Natl Acad Sci U S A (2007) 0.91
Cryosurgery would be An Effective Option for Clinically Localized Prostate Cancer: A Meta-analysis and Systematic Review. Sci Rep (2016) 0.75
Radiation-induced complex anterior urinary fistulation for prostate cancer: a retrospective multicenter study from the Trauma and Urologic Reconstruction Network of Surgeons (TURNS). World J Urol (2016) 0.75
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25
A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med (2004) 19.45
Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med (2004) 17.79
Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet (2002) 14.34
Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi) N Engl J Med (2000) 8.02
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 7.35
Heavy metal content of ayurvedic herbal medicine products. JAMA (2004) 7.33
Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys (2002) 6.82
Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet (1993) 6.56
Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA (2002) 6.21
A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group. N Engl J Med (1994) 5.98
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst (2004) 5.87
Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst (1996) 5.63
Herbal medicines and perioperative care. JAMA (2001) 5.05
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol (2003) 3.82
Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol (2003) 3.73
Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst (2003) 3.54
A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. Arch Ophthalmol (2001) 3.49
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst (1996) 2.98
Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol (2005) 2.79
Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study. Am J Clin Nutr (2001) 2.64
Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis. J Natl Cancer Inst (2005) 2.54
Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA (2003) 2.50
Bisphosphonates: clinical experience. Oncologist (2004) 2.12
Balancing the risks and benefits of fish consumption. Ann Intern Med (2004) 2.09
Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol (1999) 2.07
A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst (2005) 2.04
Urinary fistulas following external radiation or permanent brachytherapy for the treatment of prostate cancer. J Urol (2005) 2.01
Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer (2005) 1.94
Laparoscopic cholecystectomy versus mini-laparotomy cholecystectomy: a prospective, randomized, single-blind study. Ann Surg (2001) 1.88
Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys (2002) 1.85
Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys (1997) 1.65
Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol (2003) 1.60
Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys (1998) 1.58
Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys (2000) 1.54
Laparoscopic versus open radical prostatectomy: a comparative study at a single institution. J Urol (2003) 1.50
Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys (1991) 1.50
Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res (1998) 1.46
Laparoscopic radical prostatectomy: preliminary results. Urology (2000) 1.42
Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol (2005) 1.35
Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer (1999) 1.26
Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys (1999) 1.23
Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. BJU Int (2004) 1.22
A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol (2004) 1.22
Radical retropubic versus laparoscopic prostatectomy: a prospective comparison of functional outcome. Urology (2003) 1.18
Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol (1998) 1.16
Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology (2003) 1.15
Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2004) 1.15
Risk of prostate cancer in a randomized clinical trial of calcium supplementation. Cancer Epidemiol Biomarkers Prev (2005) 1.13
Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev (2005) 1.11
Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology (1999) 1.11
Extraperitoneal laparoscopic radical prostatectomy. Results after 50 cases. Eur Urol (2001) 1.10
The role of dietary supplements during cancer therapy. J Nutr (2003) 1.09
Radical prostatectomy: a prospective comparison of oncological and functional results between open and laparoscopic approaches. World J Urol (2003) 1.08
High cumulative incidence of urinary tract transitional cell carcinoma after kidney transplantation in Taiwan. Am J Kidney Dis (2004) 1.07
Laparoscopic radical prostatectomy. Technical aspects and experience with 125 cases. Eur Urol (2001) 1.06
Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer (2001) 1.06
Prostate cryoablation using direct transperineal placement of ultrathin probes through a 17-gauge brachytherapy template-technique and preliminary results. Urology (2001) 1.05
Prospective comparison of short-term convalescence: laparoscopic radical prostatectomy versus open radical retropubic prostatectomy. Urology (2003) 1.05
Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2002) 1.04
The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. Ann Intern Med (1990) 1.00
Cryosurgical treatment of the prostate. Invest Urol (1966) 0.99
Devastating complications after brachytherapy in the treatment of prostate adenocarcinoma. BJU Int (2004) 0.99
Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy. J Urol (2005) 0.99
Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma. Br J Cancer (2002) 0.98
Robotic assisted laparoscopic radical prostatectomy versus retropubic radical prostatectomy: a prospective assessment of postoperative pain. J Urol (2005) 0.96
Radical retropubic prostatectomy: morbidity and urinary continence in 418 consecutive cases. Urology (1994) 0.96
The York Mason approach to repair of iatrogenic rectourinary fistulae. Am J Surg (1997) 0.96
Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys (2003) 0.94
The evolution and state of modern technology for prostate cryosurgery. Urology (2002) 0.94
Use of complementary and alternative medicine in men with family history of prostate cancer: a pilot study. Urology (2004) 0.90
Cryoablation for clinically localized prostate cancer using an argon-based system: complication rates and biochemical recurrence. BJU Int (2000) 0.86
The value of radiotherapy in treating recurrent prostate cancer after radical prostatectomy. Nat Clin Pract Urol (2004) 0.86
Rectal bleeding after conformal 3D treatment of prostate cancer: time to occurrence, response to treatment and duration of morbidity. Int J Radiat Oncol Biol Phys (1997) 0.86
Vertebral deformity in men. J Bone Miner Res (1992) 0.86
Management of bone loss in men with prostate cancer. J Urol (2003) 0.85
Laparoscopic radical prostatectomy: the lessons learned. J Endourol (2001) 0.84
Minimizing prostate brachytherapy-related morbidity. Urology (2003) 0.84
Radiotherapy in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directions. J Clin Oncol (2005) 0.83
Successful repair of iatrogenic rectourinary fistulas using the posterior sagittal transrectal approach (York-Mason): 15-year experience. World J Surg (2006) 0.83
Cryoablation of localized prostate cancer. Experience in 48 cases, PSA and biopsy results. Eur Urol (1998) 0.83
[Perioperative and postoperative complications of pelvic lymphadenectomy and radical prostatectomy in 320 consecutive patients]. Urologe A (1995) 0.83
Rectal complications after modern radiation for prostate cancer: a colorectal surgical challenge. J Gastrointest Surg (2005) 0.82
Detection of Herba Aristolochia Mollissemae in a patient with unexplained nephropathy. Am J Kidney Dis (2005) 0.82
Beta-carotene did not work: aftermath of the ATBC study. Cancer Lett (1997) 0.80
Bone marrow necrosis: a rare complication of herbal treatment with Hypericum perforatum (St. John's wort). Acta Medica (Hradec Kralove) (2005) 0.79
Prospective evaluation of a minimally invasive approach for treatment of bile-duct calculi in the high-risk patient. Surg Endosc (1997) 0.79
Severe bone marrow depression induced by an anticancer herb Cantharanthus roseus. J Toxicol Clin Toxicol (2004) 0.77
Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading method. Int J Radiat Oncol Biol Phys (2001) 0.77
York Mason procedure for repair of postoperative rectoprostatic urethral fistula. Dis Colon Rectum (1983) 0.75
Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res (2005) 1.55
WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells. Mol Cancer Ther (2009) 1.34
Effects of the kava chalcone flavokawain A differ in bladder cancer cells with wild-type versus mutant p53. Cancer Prev Res (Phila) (2008) 1.34
Flavokawain B, a kava chalcone, induces apoptosis via up-regulation of death-receptor 5 and Bim expression in androgen receptor negative, hormonal refractory prostate cancer cell lines and reduces tumor growth. Int J Cancer (2010) 1.12
Three-dimensional sonography with needle tracking: role in diagnosis and treatment of prostate cancer. J Ultrasound Med (2008) 1.07
Rhodiola rosea extracts and salidroside decrease the growth of bladder cancer cell lines via inhibition of the mTOR pathway and induction of autophagy. Mol Carcinog (2011) 0.97
Kava chalcone, flavokawain A, inhibits urothelial tumorigenesis in the UPII-SV40T transgenic mouse model. Cancer Prev Res (Phila) (2013) 0.90
Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels. Neoplasia (2011) 0.90
Continent lower urinary tract reconstruction in the cervical spinal cord injured population. J Urol (2003) 0.89
Chemoprevention of prostate cancer with the polyamine synthesis inhibitor difluoromethylornithine. Recent Results Cancer Res (2014) 0.80